ESMO - Eur. Oncology· @myESMO · X·· 4 小时前评分70
正文 · 原文
#ESMO26: Next-generation CDK4 inhibitor atirmociclib in combination with fulvestrant extends PFS by 3 months in endocrine-resistant #AdvancedBreastCancer in the phase II FOURLIGHT-1 #ClinicalTrial
🔗 https://ow.ly/99yu5100p14
#InsightsbyESMO #BreastCancer
138 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1842O按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)
https://esmocongress.esmo.orgFOURLIGHT-1
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com